The record
| Class | growth factor |
|---|---|
| Also known as | Long R3 IGF-1, LongR3 IGF-I, LR3-IGF-1, Long Arg3 IGF-1 |
| Chain length | - |
| Molecular weight | 9,117.6 Da |
| Half-life | 5-6 hours |
| Route | Cell culture media or SC/IM (research) |
| Studied for | - |
| Research use | Cell culture growth supplement; Stem cell expansion; Muscle cell differentiation |
| What has been shown | Superior cell culture performance vs IGF-1; Extended activity in vivo; Reduced IGFBP interference; Cost-effective for cell culture |
| How it works | IGF-1 analog with 13 N-terminal extension peptide (MFPAMPLSSLFVNG) and Arg substitution at position 3. Designed to minimize IGFBP binding while maintaining IGF-1R activity. The modifications result in: (1) 200-fold reduced IGFBP affinity, (2) 3x longer half-life than IGF-1, (3) Enhanced bioavailability. Used extensively in cell culture as growth supplement. Activates same pathways as IGF-1 (PI3K/A |
| Patent status | GroPep/Novozymes patents |
| Regulatory status | Research reagent only |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Muscle Hypertrophy / Anabolic Signaling (affection, 80%)
- GH Pulsatility Environment (affection, 32%)
- Adult GH deficiency (illness, 30%)
- Anti-aging protocols (illness, 40%)
- Anti-aging therapy (illness, 30%)
- Body composition optimization (illness, 36%)
- Cardiac repair after myocardial infarction (illness, 40%)
- Duchenne muscular dystrophy (illness, 60%)
- Fat loss without muscle loss (illness, 30%)
- Growth hormone deficiency (illness, 40%)
- Metabolic syndrome (illness, 40%)
- Muscle wasting conditions (illness, 48%)
- Neuromuscular diseases (illness, 60%)
- Pediatric growth hormone deficiency (illness, 30%)
- Post-injury muscle recovery (illness, 40%)
- Post-stroke recovery (illness, 40%)
- Soft tissue repair (illness, 40%)
- Muscle loss or weakness (symptom, 67%)